INTRODUCTION
Intranasal administration is an effective way to deliver drugs into the systemic circulation as an alternative to the oral and parenteral routes for some therapeutic agents (Fig. 1) . Undoubtedly, the nasal administration of medicines has been widely used for the treatment of topical nasal conditions such as nasopharyngitis or allergic rhinitis for many years. The nasal pathway may circumvent the blood-brain barrier and allow centrally acting pharmacons a direct transport route to the central nervous system. Concerning systemic delivery, drugs can be rapidly absorbed through the nasal mucosa, resulting in a quick onset of action, and avoiding degradation in the gastrointestinal tract and first-pass metabolism in the liver.
Fig. 1: Intranasal administration of drugs. The target for drug delivery can be the nasal mucosa, the central nervous system or the systemic blood circulation.
During the formulation of a pharmaceutical dosage form intended for intranasal application, several factors should be taken into consideration. The poor solubility of a drug and its low rate of dissolution can lead to insufficient absorption or delayed therapeutical effect. Indeed the nasally administered pharmaceutical preparations will be cleared rapidly from the nasal cavity into the gastrointestinal tract by the mucociliary clearance system.
AIMS
For the development of relevant strategies to overcome biological barriers (eg. nasal mucosa) and in order to screen the feasibility of drug nanoparticles, innovative excipients and novel pharmaceutical compositions for nasal delivery targeting the systemic blood circulation, in vitro permeability models are useful and relevant tools.
The aim of my scientific work was to establish an in vitro investigational protocol for drugs intended to use in nasal delivery (Fig. 2) . The application of cell-based assays as well as conventional investigational methods of pharmaceutical technology is crucial for understanding the toxicity and efficacy of an innovative pharmaceutical composition.
Fig. 2: The steps of a nasal investigational protocol to screen innovative formulations (nanoparticles) and novel pharmaceutical excipients (permeation enhancers).
The main steps of our experiments were the following:
preparation and characterisation of meloxicam nanoparticles by co-grinding
(ii) optimization of the preparation process by factorial experiment design (iii) establishment of in vitro methods for studying permeability of drugs in nasal formulations
optimization of a culture model of the nasal system using RPMI 2650 cells (v) screen of the toxicity and efficacy of drug nanoparticles and pharmaceutical excipients by in vitro methods
MATERIALS AND METHODS

Preparation and characterization of meloxicam nanoparticles
Meloxicam (MEL) was obtained from EGIS Ltd. (Hungary). The grinding additives, polyvinylpyrrolidone (PVP) K25 and C30 were purchased from BASF (Germany).
Polyethylene glycol (PEG) 6000 and 20 000 were from Sigma-Aldrich Chemie GmbH (Germany). MEL and carriers were mixed and charged into the chamber of the planetary monomill (Fritsch Pulverisette 6, Fritsch GmbH, Germany).
Determination of particle size was performed by scanning electron microscopic image analysis. Products were washed and centrifuged to separate the excipient from the MEL, so that individual MEL particles could be studied. The particle size and the surface morphology of the MEL particles were visualised by scanning electron microscopy (SEM). Samples were fixed onto a metallic stub with double-sided conductive tape (diameter 12 mm, Oxford
Instruments, UK). Images were taken in secondary electron image mode on a Hitachi S-4700
Type II instrument (Japan) at an acceleration voltage of 10 kV.
MEL particle diameter distributions were obtained by analysing SEM images with the ImageJ software environment. Over 150 individual particle measurements were made in at least five different images in order to determine the particle size.
The following variables were the parameters featuring in the optimization (Table 1) . A full factorial design plan was created and carried out with the MEL particle size distribution defined as response factor. All calculations were performed by using Minitab 14 (Minitab Statistical Software, USA). 
Investigations of the optimized products
The physical state of MEL in the different samples was evaluated by X-ray powder diffraction (XRPD) analysis. Diffraction patterns were analysed with a Miniflex II X-ray Diffractometer (Rigaku Co., Japan).
The solubility of MEL was determined at physiological conditions (pH 7.4, 37 °C) by addition of an excess of the drug to the solvent, after which the mixture was stirred on a magnetic stirrer for 8 h, and the content of dissolved drug was analysed (Unicam UV/vis spectrophotometer, Germany). The extent of dissolution of MEL was studied in 50 mL phosphate buffer (PBS) at physiological conditions with Pharmatest equipment (Germany) at a paddle speed of 100 rpm.
Franz cell diffusion -In vitro permeability
In vitro permeability studies were performed with a vertical Franz-diffusion cell system (Hanson Research, USA) containing six cells. The donor phase contained MEL in 1 mg/mL and sodium hyaluronate in 5 mg/mL concentration, which were placed on the synthetic membrane impregnated with isopropyl myristate. Experiments were performed at 37 °C water bath. At predefined time points, samples of 0.8 mL were taken from the acceptor phase by the autosampler (Hanson Research, USA) and were replaced with fresh receiving medium.
Cell culture experiments
RPMI 2650 (ATCC cat.no. CCL 30) cells were grown in Eagle's minimal essential medium supplemented with 10% foetal bovine serum and gentamicin in a humidified 37 °C incubator with 5% CO 2 . The cells were seeded on culture dishes at a density of 5×10 5 cells/cm 2 and the medium was changed every 2 days. For the cell viability assays cells were passaged to 96-well plates, for immunohistochemistry and nucleus staining cells were cultured on glass coverslips. For permeability studies cells were cultured on Transwell filter inserts (polycarbonate membrane, Corning Costar Co., USA). All surfaces were coated with rat tail collagen before cell seeding. Cell growth and morphology were monitored using a Nikon Eclipse TE2000 microscope (Nikon, Japan).
The culture model was optimised by testing the 24-h effect of retinoic acid (RA) in three different concentrations: 0.01, 100, 300 µg/mL. Hydrocortisone (HC) was examined at 500 nM; 8-(4-chlorophenylthio) adenosine 3',5'-cyclic monophosphate sodium salt (CPTcAMP) at 250 µM in the presence of 17.5 µM 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO20-1724, Calbiochem, Germany), a phosphodiesterase inhibitor.
Electron microscopy RPMI 2650 cells grown on Transwell filter membrane were fixed. After washing with cacodylate buffer several times, the membranes of the culture inserts with the cells were removed from their support and placed into 24-well chamber slide and were postfixed in 
RESULTS AND DISCUSSION
Preparation and characterization of meloxicam nanoparticles
With PVP-C30, it was possible to decrease the average MEL particle size (d SEM ) below 250 nm and the average SD below 50%. This was a significant improvement relative to the additive-free grinding result. The optimum co-grinding parameter set for PVP-C30 was a MEL to excipient ratio 1:1, and a rotation frequency of 400 rpm. The crystallinity of MEL was decreased in the co-grinding process with PVP-C30; in the other optimized product, which contains PEG 6000 the crystallinity of MEL did not change significantly as compared to the physical mixture. The crystalline MEL was altered in the co-grinding process with the amorphous excipient, PVP-C30, leading to amorphous nanoparticles. With PEG 6000 as excipient, MEL nanocrystals were prepared and the crystallinity of MEL was proved by XRPD (Fig. 3) .
Fig. 3: X-ray powder diffraction spectra of the optimized products (1, 2), the physical mixtures of the components (4, 3) and meloxicam (5).
Dissolution of meloxicam nanoparticles
Amorphous MEL nanoparticles showed favourable dissolution properties at physiological conditions. In one hand the solubility of MEL elevated up to about 1 mg/mL (Fig. 4A) , on the other hand the extent of dissolution also increased, complete dissolution of MEL was observed in 15 min (Fig. 4B) .
Fig. 4: (A) Solubility of meloxicam (MEL) in case of the physical mixture (MEL/PVP) and the co-ground product (nanoMEL/PVP) in phosphate buffer (pH 7.4, 37 °C). (B) The extent of dissolution of MEL in case of the physical mixture (MEL/PVP) and the co-ground product (nanoMEL/PVP) in phosphate buffer (pH 7.4, 37 °C). MEL/PVP, meloxicam and polyvinylpyrrolidone C30 mass ratio 1:1.
The cumulative amount of MEL that diffused through a synthetic membrane from the different pharmaceutical compositions was measured against time (Fig. 5) . The diffusion from the composition containing MEL nanoparticles and sodium hyaluronate was quicker, 25% of MEL was released from the formulation containing MEL in nanonized form vs. 10% in case of the physical mixture in the first 2 h. (pH 7.4, 37 °C) . MEL/PVP, meloxicam and polyvinylpyrrolidone C30 mass ratio 1:1; HA, sodium hyaluronate (5 mg/mL).
Fig. 5: In vitro permeability of meloxicam through an artificial membrane in case of the physical mixture (MEL/PVP) and the coground product (nanoMEL/PVP) in phosphate buffer
In vitro cell culture model of the nasal barrier
Due to the importance of systemic nasal drug delivery there is a need for cell culture models of the nasal barrier for testing various compounds and pharmaceutical compositions.
The properties of such in vitro systems need to be compared with in vivo circumstances.
In our experiments RPMI 2650 cells grew as mono-or multilayers and reached confluence in liquid-liquid interface culture condition. The presence of intercellular junctions was confirmed by electron and immunofluorescent microscopy. Besides morphological investigations the functional properties of the nasal epithelial barrier such as resistance and paracellular permeability were also proved.
Fig. 6: Morphological characterisation of RPMI 2650 human nasal epithelial cell line. (A) Phase contrast microscopic image of the cells (bar: 25 µm) and (B) confocal microscopic image of β-catenin immunostaining (bar: 10 µm) show cobble-stone, epithelial morphology. (C) Electron microscopic image of RPMI 2650 cells where arrows indicate tight intercellular junctions (N, nucleus; M, mitochondrion; ER, endoplasmatic reticulum; TJ, tight junction; V, microvilli; bar: 250 nm).
Advantages of the presented in vitro nasal system include simplicity of culture, reproducibility, suitability for permeability studies and RT-CES. RPMI 2650 cells model the respiratory zone of the human nasal epithelium which is the most important absorption surface for nasally administered drugs to the systemic circulation. The absence of cilia and air-liquid interface can be considered as limitations of this nasal model. The presented data support that RPMI 2650 cells can be successfully used to establish an in vitro model of the nasal barrier and to test toxicity and epithelial permeability.
Permeability of meloxicam nanoparticles across the in vitro nasal barrier
To test the biological effects of the MEL nanoparticles an in vitro cell culture model of the nasal barrier, human RPMI 2650 cells were used. Impedance measured by RT-CES noninvasively quantifies adherens cell proliferation, viability and cell layer integrity. The RT-CES results indicated no sign of disruption in the integrity of the RPMI 2650 cell layers, which could be observed in the toxicity control group (Fig. 7A) .
Fig. 7: (A) Real-time cell microelecronic sensing measurement of cell viability and integrity of human RPMI 2650 nasal epithelial cells treated by vehicle and the co-ground product (nanoMEL/PVP). (B) Apparent permeability coefficients (P app ) of MEL in case of the physical mixture (MEL/PVP) and the co-ground product (nanoMEL/PVP) measured across human RPMI 2650 nasal epithelial cell layers. MEL/PVP, meloxicam and polyvinylpyrrolidone C30 mass ratio 1:1; HA, sodium hyaluronate (5 mg/mL); TX-100, TritonX-100 (10 mg/mL).
The flux of MEL through the human RPMI 2650 cell layers was significantly slower than in the case of the Franz cell diffusion model, reflecting the more complex nasal barrier model of the in vitro cell culture system. The permeability coefficient of MEL for the composition containing MEL nanoparticles and sodium hyaluronate was 1.2×10 -5 cm/s vs.
0.5×10
-5 cm/s in case of the physical mixture (Fig. 7B) .
Effects of sucrose esters and reference surfactants on epithelial barrier integrity
Sucrose esters elicited dose-dependent TEER changes (Fig. 8A-B) . At 0.1 mg/mL concentrations both laurate and myristate sucrose esters led to a significant and transient TEER decrease, while 0.3 mg/mL and higher concentrations caused an irreversible drop of TEER. Tween 80 at 10 mg/mL dose also resulted in a significant TEER decrease, while the lower concentration, similarly to 1 and 10 mg/mL concentration of Cremophor RH40 did not cause changes as compared to control group. (Fig. 9A ).
After 1-h treatment with 0.1 mg/mL laurate sucrose ester the apparent permeability coefficient of FITC-dextran was increased by 50%. Comparing the effects of sucrose esters and the reference surfactants on the permeability for the marker molecule across epithelial cell layers, the same, non-toxic concentration of 0.1 mg/mL was chosen for all compounds. All excipients increased significantly the epithelial paracellular permeability; the largest increase was seen in case of laurate sucrose ester, the P app values were elevated from 9.7×10 -6 cm/s to 1.4×10 -5 cm/s after 1-h treatment (Fig. 9B ).
SUMMARY
Novel sites of drug administration for systemic delivery and novel formulations offer numerous opportunities to develop innovative pharmaceutical compositions. The nasal pathway represents an alternative route for non-invasive systemic administration of drugs, although the nasal epithelium forms a restricting barrier. Nanonization of drugs is a great possibility to increase solubility and to augment permeability through mucosal barriers.
Pharmaceutical excipients may help to increase the solubility of active agents and enhance the permeability of molecules with larger molecular mass like peptides via the modulation of the paracellular pathway. 
